跳至主要内容
临床试验/ITMCTR1900002326
ITMCTR1900002326招募中1 期

Clinical evaluation of GanJi formulation in prevention recurrence of radical resection of primary liver cancer

Shuguang Hospial Affiliated to Shanghai University of TCM0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 65(—)
性别
All

入选标准

  • (1) patients with primary liver cancer after radical resection (BCLC stage 0, stage A);
  • (2) patients within 3 months after surgical treatment (surgery, radiofrequency ablation);
  • (3) aged 18 to 65 years, gender is not limited;
  • (4) willing to accept Chinese medicine and/or integrated Chinese and western medicine treatment;
  • (5) sign informed consent.

排除标准

  • (1) metastatic liver cancer patients, or concurrent with other cancer patients;
  • (2) Without radical surgery or with refractory ascites, hepatic encephalopathy, liver failure, portal vein embolism and other serious complications;
  • (3) accompanied by heart, kidney, lung, endocrine, blood, metabolism and gastrointestinal tract serious primary disease; Or mentally ill;
  • (4) legally disabled persons, pregnant women or nursing women;
  • (5) allergy or multiple drug allergy patients;
  • (6) patients with molecular targeted anti-tumor drugs (sorafenib).

研究者

发起方
Shuguang Hospial Affiliated to Shanghai University of TCM

相似试验

Clinical evaluation of GanJi formulation in... | 临床试验